NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures 

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Nina Bickell, MD, MPH
Harold J. Burstein, MD, PhD
Meena S. Moran, MD
Tara Sanft, MD
Jessica S. Young, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated. 

Chau T. Dang, MD
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Puma Biotechnology: Grant/Research Support
Roche/Genentech: Consulting Fee; Grant/Research Support
SeaGen: Consulting Fee

Anthony D. Elias, MD
Astellas Pharma US, Inc.: Grant/Research Support
BioAtla Inc.: Grant/Research Support
C4 Therapeutics, Inc.: Grant/Research Support
Epizyme: Grant/Research Support
Fosun Orinove Pharma Tech, Inc: Grant/Research Support
ImmuneOnco Biopharmaceuticals Co., Ltd: Grant/Research Support
Infinity Pharmaceuticals, Inc.: Grant/Research Support
PTC Therapeutics: Grant/Research Support
Quantum Leap Health Consortium: Grant/Research Support
Zenshine Pharmaceuticals: Grant/Research Support

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheronostics: Honoraria; Scientific Advisor
Daiichi-Sankyo co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor

Rachel C. Jankowitz, MD
Biotheranostics: Scientific Advisor

Ami Shah, MD
AstraZeneca Pharmaceuticals LP: Honoraria
Gilead Sciences, Inc.: Honoraria

Hatem Soliman, MD
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
Merck & Co., Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee
Puma Biotechnology: Consulting Fee
SeaGen: Consulting Fee

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.